Advertisement

Clinical Pharmacokinetics

, Volume 42, Issue 4, pp 315–325 | Cite as

Pharmacokinetic Principles of Bacteriophage Therapy

  • Robert J. H. PayneEmail author
  • Vincent A. A. Jansen
Leading Article

Abstract

Use of bacteriophage to control bacterial infections, including antibioticresistant infections, shows increasing therapeutic promise. Effective bacteriophage therapy requires awareness of various novel kinetic phenomena not known in conventional drug treatments. Kinetic theory predicts that timing of treatment could be critical, with the strange possibility that inoculations given too early could be less effective or fail completely. Another paradoxical result is that adjuvant use of an antibiotic can sometimes diminish the efficacy of phage therapy. For a simple kinetic model, mathematical formulae predict the values of critical density thresholds and critical time points, given as functions of independently measurable biological parameters. Understanding such formulae is important for interpreting data and guiding experimental design. Tailoring pharmacokinetic models for specific systems needs to become standard practice in future studies.

Keywords

Bacterial Density Active Therapy Conventional Drug Phage Therapy Inoculation Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Dr Robert J. H. Payne is funded by a Royal Society University Research Fellowship. No other sources of funding were used to assist in the preparation of this manuscript. The authors have no potential conflicts of interest directly relevant to the contents of this manuscript.

References

  1. 1.
    Sharp R. Bacteriophages: biology and history. J Chem Tech Biotechnol 2001; 76: 667–72CrossRefGoogle Scholar
  2. 2.
    d’Herelle F. Sur un microbe invisible antagoniste des bacilles dysenteriques. C R Acad Sci 1917; 165: 373–5Google Scholar
  3. 3.
    Sulakvelidze A, Alavidze Z, Morris JG. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45: 649–59PubMedCrossRefGoogle Scholar
  4. 4.
    Berkowitz FE. Antibiotic resistance in bacteria. South Med J 1995; 88: 797–804PubMedCrossRefGoogle Scholar
  5. 5.
    Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 1996; 275: 300–4PubMedCrossRefGoogle Scholar
  6. 6.
    File TM. Overview of resistance in the 1990s. Chest 1999; 115 (3 Suppl.): 3S–8SPubMedCrossRefGoogle Scholar
  7. 7.
    Payne RJH, Jansen VAA. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther 2000; 68: 225–9PubMedCrossRefGoogle Scholar
  8. 8.
    Payne RJH, Jansen VAA. Understanding bacteriophage therapy as a density-dependent kinetic process. J Theor Biol 2001; 208: 37–48PubMedCrossRefGoogle Scholar
  9. 9.
    Alisky J, Iczkowski K, Rapoport A, et al. Bacteriophage show promise as antimicrobial agents. J Infect 1998; 36: 5–15PubMedCrossRefGoogle Scholar
  10. 10.
    Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol 1997; 5: 268–71PubMedCrossRefGoogle Scholar
  11. 11.
    Barrow PA. The use of bacteriophages for treatment of bacterial disease in animals and animal models of human infection. J Chem Tech Biotechnol 2001; 76: 677–82CrossRefGoogle Scholar
  12. 12.
    Chanishvili N, Chanishvili T, Tediashvili M, et al. Phages and their application against drug-resistant bacteria. J Chem Tech Biotechnol 2001; 76: 689–99CrossRefGoogle Scholar
  13. 13.
    Bacterial Ecology Group. Phage therapy references [online]. Available from: http://www.phage.org/bib_pt.htm [Accessed 2003 Jan 29]
  14. 14.
    Slopek S, Weber-Dabrowska B, Dabrowski M, et al. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz) 1987; 35: 569–83Google Scholar
  15. 15.
    Cislo M, Dabrowski M, Slopek S. Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 1987; 35: 175–83Google Scholar
  16. 16.
    Weber-Dabrowska B, Dabrowski M, Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 563–8Google Scholar
  17. 17.
    Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. Arch Immunol Ther Exp (Warsz) 1987; 35: 553–61Google Scholar
  18. 18.
    Abdul-Hassan HS, El-Tahan E, Massoud B, et al. Bacterio-phage therapy of Pseudomonas burn wound sepsis. Ann Medit Burn Club 1990; 3: 262–4Google Scholar
  19. 19.
    Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129: 2659–75PubMedGoogle Scholar
  20. 20.
    Smith HW, Huggins MB, Shaw KM. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J Gen Microbiol 1987; 133: 1111–26PubMedGoogle Scholar
  21. 21.
    Berchieri A, Lovell MA, Barrow PA. The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium. Res Microbiol 1991; 142: 541–9PubMedCrossRefGoogle Scholar
  22. 22.
    Soothill JS. Treatment of experimental infection of mice with bacteriophages. J Med Microbiol 1992; 37: 258–61PubMedCrossRefGoogle Scholar
  23. 23.
    Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20: 209–11PubMedCrossRefGoogle Scholar
  24. 24.
    Barrow P, Lovell M, Berchieri A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chicken and calves. Clin Diag Lab Immun 1998; 5: 294–8Google Scholar
  25. 25.
    Ramesh V, Fralick JA, Rolfe RD. Prevention of Clostridium difficile-induced ileocecitis with bacteriophage. Anaerobe 1999; 5: 69–78CrossRefGoogle Scholar
  26. 26.
    Nakai T, Sugimoto R, Park KH, et al. Protective effects of bacteriophage on experimental Lactococcus garvieae infection in yellowtail. Dis Aquat Organ 1999; 37: 33–41PubMedCrossRefGoogle Scholar
  27. 27.
    Park SC, Shimamura I, Fukunaga M, et al. Isolation of bacteriophages specific to a fish pathogen, Pseudomonas plecoglossicida, as a candidate for disease control. Appl Environ Microbiol 2000; 66: 1416–22PubMedCrossRefGoogle Scholar
  28. 28.
    Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307–18PubMedGoogle Scholar
  29. 29.
    Cao J, Sun Y-Q, Berglindh T, et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth. Biochim Biophys Acta 2000; 1474: 107–13PubMedCrossRefGoogle Scholar
  30. 30.
    Gotelli NJ. A primer of ecology. Sunderland (MA): Sinauer, 1998Google Scholar
  31. 31.
    Anderson RM, May RM. Infectious diseases of humans. Oxford (UK): Oxford University Press, 1992Google Scholar
  32. 32.
    Campbell A. Conditions for the existence of bacteriophage. Evolution 1961; 15: 153–65CrossRefGoogle Scholar
  33. 33.
    Levin BR, Stewart FM, Chao L. Resource-limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. Am Nat 1977; 111: 3–24CrossRefGoogle Scholar
  34. 34.
    Schrag SJ, Mittler JE. Host-parasite coexistence: the role of spatial refuges in stabilizing bacteria-phage interactions. Am Nat 1996; 148: 348–77CrossRefGoogle Scholar
  35. 35.
    Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int J Tuberc Lung Dis 1998; 2: 187–99PubMedGoogle Scholar
  36. 36.
    Slopek S, Durlakowa I, Weber-Dabrowska B, et al. Results of bacteriophage treatment of suppurative bacterial infections I: general evaluation of the results. Arch Immunol Ther Exp (Warsz) 1983; 31: 267–91Google Scholar
  37. 37.
    Sakandelidze VM. Kompleksnoe primenie spetsificheskikh fagov i antibiotikov pri razlichnykh infektsionnykh allergozakh. [The combined use of specific phages and antibiotics in different infectious allergoses] [in Russian]. Vrach Delo 1991; 3: 60–3PubMedGoogle Scholar
  38. 38.
    Levin BR, Bull JJ. Phage therapy revisited: the population biology of a bacterial infection and its treatment with bacteriophage and antibiotics. Am Nat 1996; 147: 881–98CrossRefGoogle Scholar
  39. 39.
    Bull JJ, Levin BR, DeRouin T, et al. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol 2002 Nov 26; 2(1): 35PubMedCrossRefGoogle Scholar
  40. 40.
    Hawkins BA, Cornell HV, editors. Theoretical approaches to biological control. Cambridge (UK): Cambridge University Press, 1999Google Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  1. 1.School of Biological Sciences, Royal HollowayUniversity of LondonLondonUK

Personalised recommendations